Clinical Trial Update: AZD9291 in Combination With Ascending Doses of Novel Therapeutics [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AZD9291 (osimertinib) in combination with escalating doses of novel therapies for advanced non-small cell lung cancer; the trial is act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Non Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING